Abstract
and nicastrin. ␤-Secretase mediated cleavage of APP gives rise to a soluble N-terminal fragment (␤APPs) and a membrane bound C-terminal fragment (CTF-␤), which is further cleaved by ␥-secretase to release A␤, which consists of 40-43 amino acids. APP, which has been well conserved throughout evolution, is present in almost all cells and is abundantly expressed in neural cells. Its physiological role has not been clarified, although some studies have found APP to have neuroprotective or neurotrophic functions. Genes encoding PSEN1 and PSEN2 and APP have been identified as causal in early-onset familial AD (FAD). FAD-linked mutations in these genes, with an autosomal mode of inheritance, give rise to aggressive pathology and increase either the total A␤ level or the ratio of A␤42/A␤40. A␤42 is more hydrophobic and more prone to aggregate than A␤40. These observations strongly imply a cause-and-effect relationship between A␤ accumulation and AD pathogenesis. However, amyloid plaques might not necessarily be the major cause underlying neuronal cell death, synaptic loss and eventually brain atrophy in AD. There is evidence that soluble A␤-oligomers, rather than amyloid plaques, are the major pathological species causing impaired synaptic and neuronal functions. For example, it has been shown that A␤ oligomers are highly toxic, block long-term potentiation (LTP), trigger synaptic retraction and lead to impairment of memory and cognitive functions [2]. On the other hand, amyloid plaques (A␤ fibrils) cause proliferation and activation of glial cells, which secrete cytotoxic factors, and may thus be indirectly involved in neuronal dysfunction. It should be noted, however, that none of the transgenic mouse models that accumulate A␤ oligomers and A␤ plaques have reproduced the neurodegenerative pathologies, so that none of the hypothesis can be considered experimentally proven. Recently it has been shown that also A␤43 is a component of extracellular plaques in AD brains and may play a role in aggregation ([3] and Saito and Saido [personal communication]). It has been suggested that certain receptors could be involved in A␤ binding, and recent studies have shown that A␤ bound to cellular prion protein or ␣7 nicotinic acetylcholine receptor (␣7nAChR) causes neuropathology, providing further support for a pathophysiological role of A␤ in AD
 [4] [5] [6] 
. Overall, there is considerable evidence that concentration-dependent A␤ aggregation is one of the major underlying causes of AD, although other factors are also likely to contribute including hyperphosphorylated tau, apolipoprotein E (APOE)-associated lipid metabolism and inflammation
. [10, 11] ). Among these proteases, neprilysin has been identified as the major A␤-degrading enzyme [12] , while the contributions of ECE and IDE appear to be minor [10] . The [14] . Gene therapy temporarily faced a setback related to the safety of the use of viral vectors (see Table 1 for a summary of viral vectors used in gene therapy and their properties). For example, in a clinical trial of gene therapy for X-linked severe combined immunodeficiency using retroviruses [15, 16] , genetic material from the viral vector was inserted into the proximity of an LMO2 oncogene, leading to leukaemia in five patients, of whom one died [17] [18] [19] [27, 28] . Furthermore, proNGF, which is more abundant than NGF [29] , is believed to be involved in apoptotic cell signalling through binding to the p75 receptor [30] . Table 1 [27] ).
A␤ is constantly metabolized in the brain and increased steadystate levels of A␤ may be caused not only by elevated production of A␤, but also by diminished degradation of A␤. Several proteases have been implicated in A␤ degradation; neprilysin, insulindegrading enzyme (IDE), cathepsin B, matrix metalloproteinases, plasmin, endothelin-converting enzyme (ECE) and angiotensinconverting enzyme (ACE) (reviewed in

for a summary of viral vectors used in gene therapy and their properties). AAV, which is able to infect both dividing and
BDNF levels in AD
The BDNF level in brain is decreased not only in AD [68] [69] [70] [71] [72] [73] , but also in PD [74] , Huntington's disease [75] , depression [76, 77] and schizophrenia [78] . Thus [82] . On the other hand, one extensive study (n ϭ 465) found no significant difference in serum BDNF between patients with dementia and healthy elderly [83] . However, the patients were not divided into subgroups depending on their clinical stage of AD. BDNF has also been identified in cerebrospinal fluid (CSF) , where the level is 3000-fold lower than in serum [84] . [10, 11, 103] [111] [112] [113] [114] , while others found no genetic association [115] [116] [117] [118] . The expression of neprilysin at the cell membrane can be stimulated by somatostatin [119] , a neuropeptide that is involved in inhibition of growth hormone secretion and is downregulated upon aging [120] [125] . In a recent study on a large number of AD and control brain samples, the neprilysin levels were significantly increased in AD when the levels were adjusted for neuronal loss. However, the levels decrease with age [126] [108] (Fig. 1 [128] . Further, gene transfer of neprilysin using a rAAV vector, injected into the hippocampal formation of neprilysin KO mice, led to prominent expression of enzymatically active neprilysin. The activity was not confined to cell soma around the injection site, but was further transported along the neuronal projections from the ipsilateral to the contralateral hippocampus, where neprilysin was localized at pre-synaptic sites [108] . Importantly, gene delivery of neprilysin led to efficient degradation of soluble and insoluble A␤ in both neprilysin knockout mice and APP transgenic mice. [108] . [132] . Two [7, 137, 138] [103, 147] . ECE, which has an extracellular zinc binding active site, is involved in the proteolytic processing of big endothelins, which are peptides considered to regulate a number of physiological functions including vasoconstriction of blood vessels. In the brain, ECE is localized to neurons in hippocampus and layer V of cerebral cortex [148, 149] 
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possibly reflecting an induction of neprilysin expression in response to the high concentration of A␤ present during the transition from MCI to AD. Lastly, down-regulation of somatostatin (see above) upon aging, and the even more pronounced down-regulation in AD, could be one reason behind the decrease of neprilysin. These data clearly show that (i) neprilysin is the major A␤-degrading enzyme (ii ) neprilysin is down-regulated upon aging, (iii ) down-regulation of neprilysin most likely contributes to insufficient catabolism resulting in A␤ accumulation and prodromal AD. Thus, gene delivery of neprilysin could be a useful therapeutic tool to reduce A␤ levels in AD.
Gene delivery of neprilysin in AD animal models Several studies in animals have indeed shown that gene delivery of neprilysin can efficiently rescue the catabolic pathway and reduce A␤ levels
and Table 2). Firstly, neprilysin expressed in vitro using a Sindbis viral vector in murine primary cortical neurons decreased the levels of both intra-and extracellular A␤ [127]. Secondly, neprilysin gene transfer by a lentiviral vector, expressed under the control of a CMV promoter and injected into the hippocampus and the frontal cortex of APP transgenic mice, gave rise to cell soma-localized neprilysin and significantly lowered A␤ plaque burden at the ipsilateral side, but not the contralateral side
Fig. 1 Expression profiles of neprilysin in brain after rAAV5-mediated gene transfer. Expression pattern of neprilysin in the brains was visualized by immunohistochemical staining using an anti-neprilysin antibody. (A) and (B) show typical immunostaining patterns for wild-type and neprilysinknockout mouse brains, respectively. (C) rAAV5 carrying human neprilysin gene was injected into the lateral entorhinal cortex of neprilysin-knockout mice, and the brain section was immunostained 4 weeks after the injection. The expression of exogenous neprilysin is not only observed in the injection site, lateral entorhinal cortex (arrow), but also occurs in the dentate gyrus (arrowhead), which is the projection site of the lateral entorhinal cortex, and led to increased degradation of A␤. Thus, neprilysin gene delivery gives a widespread pre-synaptic distribution of exogenous neprilysin and could protect the synaptic function of AD-vulnerable neuronal circuits from A␤ pathology via a reduction of A␤ levels, indicating its potential of gene therapy for AD. Adopted with permission from
Virus-mediated gene delivery to cells or tissues is not only a therapeutic tool, but also offers the possibility of creating new animal models by transduction of mutant genes which induce certain pathologies. In one such AD mouse model, the introduction of mutant APP bearing the Swedish double mutations (K670N/M671L) into mouse brain by a replication-deficient herpes simplex virus (HSV) vector successfully induced high A␤ production [129]. Co-infection of HSV carrying the neprilysin gene in the mouse model lowered the A␤40 levels by 50% in the hippocampus. In comparison with the rAAV mediated gene delivery of neprilysin, HSV mediated transduction did not lead to widespread expression of neprilysin. Instead, the expression was confined to the ipsilateral hippocampus, being similar to that seen in the case of lentiviral delivery. One possible mechanism explaining the differences in axonal transport of neprilysin is the variation in the 5Ј and 3Ј UTR in the different viral vectors, which could influence e.g. axonal transport of the mRNA. Another possibility is variation in infection efficiency of the virus, as well as in serotypes. A more widespread distribution of neprilysin following gene delivery would imply a more efficient therapy covering larger areas of the brain. On the other hand, it is possible that neprilysin is also involved in degradation of other physiological peptides, which may lead to adverse effects. In a search for neuropeptides which may undergo processing by neprilysin, it was found that overexpression of neprilysin was associated with increased proteolytic cleavage of NPY [130]. Interestingly, the resulting CTF of NPY exhibited a neuroprotective function in vivo, suggesting that gene delivery of neprilysin would have two disease-modifying effects, i.e. increasing both the degradation of pathogenic A␤ and the production of the neuroprotective NPY fragment. Ex vivo delivery of a soluble form of neprilysin, in which the transmembrane domain is changed to a signal peptide sequence that induces secretion, was achieved by using grafts of primary fibroblasts transduced with a lentiviral vector and led to a distal reduction of A␤ plaque burden in an AD mouse model [131]. In another study, positive long-term effects, including reduction of A␤ deposition in the cerebral cortex and the hippocampus and improvement of water maze performance, were observed 6 months after injection of a lentiviral vector carrying the neprilysin gene
Potential gene therapy target candidates APOE
APOE is a 299-amino-acid protein involved in metabolism and transport of lipids including cholesterol and triglycerides. APOE is highly expressed in the liver and in the brain and plays an important role in the delivery of lipoproteins to neurons. In the brain, APOE is mainly expressed in astrocytes and microglia, from which APOE is released to extracellular space. APOE is the genetic risk factor that is most strongly associated with susceptibility to AD (recently reviewed in
ECE
ECE is another membrane-integrated protease implicated in A␤ degradation (existing in the two isoforms ECE1 and ECE2)
Down-regulation of AD-associated proteins by siRNA BACE1
The initial step in A␤ generation is ␤-secretase cleavage of APP at the extracellular N-terminal site of A␤, and is performed by the aspartic protease BACE1 (reviewed in [164] [166] . Therefore, if BACE1 is to be targeted, it will be crucial to obtain a well controlled down-regulation.
Increased levels of both BACE1 mRNA and protein have been observed in the brain at late stages of AD development [167] [168] [169] . 
